BCX9930

45 days later, BioCryst abandons another program, citing stiff competition
Fierce Biotech
Thu, 12/15/22 - 11:07 am
Biocryst
ASH 2022
BCX9930
BioCryst's Orladeyo Launch Overshadowed by FDA Hold on PNH Asset
BioSpace
Sun, 05/8/22 - 12:09 pm
Biocryst
Orladeyo
earnings
BCX9930
BioCryst halts enrollment in all studies for its lead pipeline candidate — shares crash
Endpoints
Fri, 04/8/22 - 10:47 am
Biocryst
clinical trials
BCX9930
PNH
BioCryst gets massive cash infusion to the tune of $350M, thanks to old and new investors
Endpoints
Mon, 11/22/21 - 10:12 pm
Biocryst
Royalty Pharma
BCX9930
Biocryst looks to raise the profile of its factor D inhibitor
EP Vantage
Tue, 02/23/21 - 10:33 am
Biocryst
factor D inhibitors
BCX9930